Prof. Mojisola Adeyeye, Director-General of NAFDAC

Healthcare: Regulator cautions consumers against fake Proximexa suspension

*Genuine Proximexa suspension 125mg/5ml (Cefuroxime Axetil 125mg/5ml) Batch No. C830116, manufactured by Glaxo Operations UK Limited, and manufactured Sept. 2017 expired Sept. 2019, says NAFDAC

Alexander Davis | ConsumerConnect

In an effort at protecting the health of consumers against the use of a counterfeit antibiotic drug, Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) has warned against buying and consumption of falsified Proximexa Suspension 125mg/5ml, with Lot No. C830116 currently in circulation in the country.

Prof. Mojisola Adeyeye, Director-General of NAFDAC, in a statement disclosed this Thursday, September 17, in Abuja, FCT.

The NAFDAC Director-General said Allen and Hanburys (A&H) Pharmaceutical Nigeria Limited had informed the regulatory agency about the circulation of the drug currently in retail outlets in the country.

Adeyeye noted that the falsified Proximexa suspension 125mg/5ml Lot No. C830116 was labelled with fictitious manufactured date with Sept. 2019 and to expire in Sept. 2022.

The drug, which was manufactured by Glaxo Operations UK Limited, was packaged to make it appear genuine, she said.

The NAFDAC Chief urged Nigerians to desist from purchasing and consuming the drug brand henceforth.

She stated that the genuine Proximexa suspension 125mg/5ml (Cefuroxime Axetil 125mg/5ml) with Batch No. C830116, manufactured by Glaxo Operations UK Limited, has its manufacturing date as Sept. 2017, which expired on Sept. 2019.

She, however, clarified that the genuine Proximexa suspension 125mg/5ml manufactured by Glaxo Operations UK Limited was registered by NAFDAC with NAFDAC Registration No. A4-6143.

According to her, the genuine Proximexa suspension 125mg/5ml “is an antibiotic drug used in treating a wide variety of material infections including bronchitis, urinary tract infections and pneumonia.’’

Adeyeye as well confirmed that Glaxo Operations UK Limited had also confirmed that it did not manufacture the falsified proximexa suspension 125mg/5ml.

The NAFDAC Director-General implored importers, wholesalers and retailers to desist from illegal importation, distribution and sale of the falsified product in Nigera.

Meanwhile, surveillance has been strengthened by NAFDAC at all ports of entry to prevent illegal importation of the falsified Proximexa suspension 125mg/5ml.

The agency has also heightened surveillance in the 36 states and FCT to prevent distribution and sale of the said drug, said Adeyeye.

Kindly Share This Story